Bh3 Mimetics - Cell Biology

Relevant Publications

Guideline for treating relapsed or refractory myeloid leukemia in children with Down syndrome.

Issue Release: 2024

Coupling Kinesin Spindle Protein and Aurora B Inhibition with Apoptosis Induction Enhances Oral Cancer Cell Killing.

Issue Release: 2024

Comparative analysis of Bcl-2 family protein overexpression in CAR T cells alone and in combination with BH3 mimetics.

Issue Release: 2024

MCL1 inhibition targets Myeloid Derived Suppressors Cells, promotes antitumor immunity and enhances the efficacy of immune checkpoint blockade.

Issue Release: 2024

Revisiting sensitivity of senescent cells to BH3 mimetics.

Issue Release: 2024

Identification of a novel form of caspase-independent cell death triggered by BH3-mimetics in diffuse large B-cell lymphoma cell lines.

Issue Release: 2024

Innovative Combinations, Cellular Therapies and Bispecific Antibodies for Chronic Lymphocytic Leukemia: A Narrative Review.

Issue Release: 2024

Getting more bang for their buck: BCL2 inhibitors boost dendritic-cell function to enhance anti-cancer immune surveillance.

Issue Release: 2024

The heart of VIALE-A: Cardiac complications of hypomethylating agents and venetoclax in acute myeloid leukaemia.

Issue Release: 2024

Correction: Cyclin E/Cdk2-dependent phosphorylation of Mcl-1 determines its stability and cellular sensitivity to BH3 mimetics.

Issue Release: 2024

Effective Targeting of Melanoma Cells by Combination of Mcl-1 and Bcl-2/Bcl-x/Bcl-w Inhibitors.

Issue Release: 2024

A novel inhibitory BAK antibody enables assessment of non-activated BAK in cancer cells.

Issue Release: 2024

FLT3 and IRAK4 Inhibitor Emavusertib in Combination with BH3-Mimetics in the Treatment of Acute Myeloid Leukemia.

Issue Release: 2024

Proteasome Inhibition Induces Apoptosis Through Simultaneous Inactivation of MCL-1/BCL-XL by NOXA Independent of CHOP and JNK Pathways.

Issue Release: 2024

Overview of BH3 mimetics in ovarian cancer.

Issue Release: 2024

Mitochondrial bioenergetics as a cell fate rheostat for responsive to Bcl-2 drugs: New cues for cancer chemotherapy.

Issue Release: 2024

Strategies for overcoming resistance to Bruton\'s tyrosine kinase inhibitor zanubrutinib.

Issue Release: 2024

Quantitative systems pharmacology modeling of tumor heterogeneity in response to BH3-mimetics using virtual tumors calibrated with cell viability assays.

Issue Release: 2024

Decreased apoptotic priming and loss of BCL-2 dependence are functional hallmarks of Richter\'s syndrome.

Issue Release: 2024

Synergy of retinoic acid and BH3 mimetics in MYC(N)-driven embryonal nervous system tumours.

Issue Release: 2024

What are Extremophiles?

How Does Radiation Therapy Affect Cells?

What is the Nucleus?

What is Molecular Cloning?

What Happens to Cells in Type 1 Diabetes?

How Does It Work?

What Are the Advantages of Using CT Scans in Cell Biology?

What Are Agonistic Antibodies?

What are the Therapeutic Implications of Autophagy?

What Is the Biological Significance of Death Receptors?

Partnered Content Networks

Relevant Topics